-
1
-
-
77957200763
-
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d'Etudes des Lymphomes de l'Adulte
-
Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010;116:2040-5.
-
(2010)
Blood
, vol.116
, pp. 2040-2045
-
-
Coiffier, B.1
Thieblemont, C.2
Van Den Neste, E.3
Lepeu, G.4
Plantier, I.5
Castaigne, S.6
-
2
-
-
84857942952
-
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing
-
Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A 2012;109:3879-84.
-
(2012)
Proc Natl Acad Sci U S A
, vol.109
, pp. 3879-3884
-
-
Lohr, J.G.1
Stojanov, P.2
Lawrence, M.S.3
Auclair, D.4
Chapuy, B.5
Sougnez, C.6
-
3
-
-
51649111684
-
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways
-
Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A 2008;105:13520-5.
-
(2008)
Proc Natl Acad Sci U S A
, vol.105
, pp. 13520-13525
-
-
Lenz, G.1
Wright, G.W.2
Emre, N.C.3
Kohlhammer, H.4
Dave, S.S.5
Davis, R.E.6
-
4
-
-
84872856782
-
Genetic heterogeneity of diffuse large B-cell lymphoma
-
Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA, et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A 2013;110:1398-403.
-
(2013)
Proc Natl Acad Sci U S A
, vol.110
, pp. 1398-1403
-
-
Zhang, J.1
Grubor, V.2
Love, C.L.3
Banerjee, A.4
Richards, K.L.5
Mieczkowski, P.A.6
-
5
-
-
18244409933
-
Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning
-
Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nature Med 2002;8:68-74.
-
(2002)
Nature Med
, vol.8
, pp. 68-74
-
-
Shipp, M.A.1
Ross, K.N.2
Tamayo, P.3
Weng, A.P.4
Kutok, J.L.5
Aguiar, R.C.6
-
6
-
-
0034598746
-
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
-
Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-11.
-
(2000)
Nature
, vol.403
, pp. 503-511
-
-
Alizadeh, A.A.1
Eisen, M.B.2
Davis, R.E.3
Ma, C.4
Lossos, I.S.5
Rosenwald, A.6
-
7
-
-
0043192901
-
A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma
-
Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 2003;100:9991-6.
-
(2003)
Proc Natl Acad Sci U S A
, vol.100
, pp. 9991-9996
-
-
Wright, G.1
Tan, B.2
Rosenwald, A.3
Hurt, E.H.4
Wiestner, A.5
Staudt, L.M.6
-
8
-
-
27644488026
-
Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction
-
Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V, et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 2005;106:3183-90.
-
(2005)
Blood
, vol.106
, pp. 3183-3190
-
-
Bea, S.1
Zettl, A.2
Wright, G.3
Salaverria, I.4
Jehn, P.5
Moreno, V.6
-
9
-
-
79952579476
-
Signatures of murine B-cell development implicate Yy1 as a regulator of the germinal center-specific program
-
Green MR, Monti S, Dalla-Favera R, Pasqualucci L, Walsh NC, Schmidt-Supprian M, et al. Signatures of murine B-cell development implicate Yy1 as a regulator of the germinal center-specific program. Proc Natl Acad Sci U S A 2011;108:2873-8.
-
(2011)
Proc Natl Acad Sci U S A
, vol.108
, pp. 2873-2878
-
-
Green, M.R.1
Monti, S.2
Dalla-Favera, R.3
Pasqualucci, L.4
Walsh, N.C.5
Schmidt-Supprian, M.6
-
10
-
-
23744450399
-
Advances in the biology and therapy of diffuse large B-cell lymphoma: Moving toward a molecularly targeted approach
-
Abramson JS, Shipp MA. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 2005;106:1164-74.
-
(2005)
Blood
, vol.106
, pp. 1164-1174
-
-
Abramson, J.S.1
Shipp, M.A.2
-
11
-
-
57149089307
-
Stromal gene signatures in large-B-cell lymphomas
-
Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008;359:2313-23.
-
(2008)
N Engl J Med
, vol.359
, pp. 2313-2323
-
-
Lenz, G.1
Wright, G.2
Dave, S.S.3
Xiao, W.4
Powell, J.5
Zhao, H.6
-
12
-
-
9144237554
-
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
-
Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-82.
-
(2004)
Blood
, vol.103
, pp. 275-282
-
-
Hans, C.P.1
Weisenburger, D.D.2
Greiner, T.C.3
Gascoyne, R.D.4
Delabie, J.5
Ott, G.6
-
13
-
-
68549124173
-
A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy
-
Choi WW, Weisenburger DD, Greiner TC, Piris MA, Banham AH, Delabie J, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009;15:5494-502.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 5494-5502
-
-
Choi, W.W.1
Weisenburger, D.D.2
Greiner, T.C.3
Piris, M.A.4
Banham, A.H.5
Delabie, J.6
-
14
-
-
79951990286
-
Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab
-
Meyer PN, Fu K, Greiner TC, Smith LM, Delabie J, Gascoyne RD, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 2011;29:200-7.
-
(2011)
J Clin Oncol
, vol.29
, pp. 200-207
-
-
Meyer, P.N.1
Fu, K.2
Greiner, T.C.3
Smith, L.M.4
Delabie, J.5
Gascoyne, R.D.6
-
15
-
-
84890766832
-
Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: Implications for therapeutic strategies
-
Coutinho R, Clear AJ, Owen A, Wilson A, Matthews J, Lee A, et al. Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies. Clin Cancer Res 2013;19:6686-95.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 6686-6695
-
-
Coutinho, R.1
Clear, A.J.2
Owen, A.3
Wilson, A.4
Matthews, J.5
Lee, A.6
-
16
-
-
84887823331
-
Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients
-
Culpin RE, Sieniawski M, Angus B, Menon GK, Proctor SJ, Milne P, et al. Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients. Histopathology 2013;63:788-801.
-
(2013)
Histopathology
, vol.63
, pp. 788-801
-
-
Culpin, R.E.1
Sieniawski, M.2
Angus, B.3
Menon, G.K.4
Proctor, S.J.5
Milne, P.6
-
17
-
-
79955944673
-
Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy
-
Gutierrez-Garcia G, Cardesa-Salzmann T, Climent F, Gonzalez-Barca E, Mercadal S, Mate JL, et al. Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood 2011;117:4836-43.
-
(2011)
Blood
, vol.117
, pp. 4836-4843
-
-
Gutierrez-Garcia, G.1
Cardesa-Salzmann, T.2
Climent, F.3
Gonzalez-Barca, E.4
Mercadal, S.5
Mate, J.L.6
-
18
-
-
78649742465
-
Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL
-
Ott G, Ziepert M, Klapper W, Horn H, Szczepanowski M, Bernd HW, et al. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood 2010;116:4916-25.
-
(2010)
Blood
, vol.116
, pp. 4916-4925
-
-
Ott, G.1
Ziepert, M.2
Klapper, W.3
Horn, H.4
Szczepanowski, M.5
Bernd, H.W.6
-
19
-
-
84899136028
-
Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue
-
Scott DW, Wright GW, Williams PM, Lih CJ, Walsh W, Jaffe ES, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood 2014;123:1214-7.
-
(2014)
Blood
, vol.123
, pp. 1214-1217
-
-
Scott, D.W.1
Wright, G.W.2
Williams, P.M.3
Lih, C.J.4
Walsh, W.5
Jaffe, E.S.6
-
20
-
-
0038243177
-
Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma
-
Pasqualucci L, Migliazza A, Basso K, Houldsworth J, Chaganti RS, Dalla-Favera R. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. Blood 2003;101:2914-23.
-
(2003)
Blood
, vol.101
, pp. 2914-2923
-
-
Pasqualucci, L.1
Migliazza, A.2
Basso, K.3
Houldsworth, J.4
Chaganti, R.S.5
Dalla-Favera, R.6
-
21
-
-
53249123632
-
-
Lyon (France): IARC Press
-
Swerdlow S, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumours of haematopoeitic and lymphoid tissues. 4th ed. Lyon (France): IARC Press; 2008.
-
(2008)
WHO Classification of Tumours of Haematopoeitic and Lymphoid Tissues. 4th Ed.
-
-
Swerdlow, S.1
Campo, E.2
Harris, N.L.3
Jaffe, E.S.4
Pileri, S.A.5
Stein, H.6
-
22
-
-
84865962469
-
Gray zone lymphoma: Better treated like Hodgkin lymphoma or mediastinal large B-cell lymphoma?
-
Dunleavy K, Grant C, Eberle FC, Pittaluga S, Jaffe ES, Wilson WH. Gray zone lymphoma: better treated like Hodgkin lymphoma or mediastinal large B-cell lymphoma? Curr Hematol Malig Rep 2012;7:241-7.
-
(2012)
Curr Hematol Malig Rep
, vol.7
, pp. 241-247
-
-
Dunleavy, K.1
Grant, C.2
Eberle, F.C.3
Pittaluga, S.4
Jaffe, E.S.5
Wilson, W.H.6
-
23
-
-
84898058507
-
Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma
-
Gunawardana J, Chan FC, Telenius A, Woolcock B, Kridel R, Tan KL, et al. Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma. Nat Genet 2014;46:329-35.
-
(2014)
Nat Genet
, vol.46
, pp. 329-335
-
-
Gunawardana, J.1
Chan, F.C.2
Telenius, A.3
Woolcock, B.4
Kridel, R.5
Tan, K.L.6
-
24
-
-
0141672946
-
Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma
-
Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003;198:851-62.
-
(2003)
J Exp Med
, vol.198
, pp. 851-862
-
-
Rosenwald, A.1
Wright, G.2
Leroy, K.3
Yu, X.4
Gaulard, P.5
Gascoyne, R.D.6
-
25
-
-
84907058311
-
A prospective study of mediastinal gray zone lymphoma
-
Wilson WH, Pittaluga S, Nicolae A, Camphausen K, Shovlin M, Steinberg SM, et al. A prospective study of mediastinal gray zone lymphoma. Blood 2014;124:1563-9.
-
(2014)
Blood
, vol.124
, pp. 1563-1569
-
-
Wilson, W.H.1
Pittaluga, S.2
Nicolae, A.3
Camphausen, K.4
Shovlin, M.5
Steinberg, S.M.6
-
26
-
-
0027394689
-
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma
-
Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-6.
-
(1993)
N Engl J Med
, vol.328
, pp. 1002-1006
-
-
Fisher, R.I.1
Gaynor, E.R.2
Dahlberg, S.3
Oken, M.M.4
Grogan, T.M.5
Mize, E.M.6
-
27
-
-
3242802160
-
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL
-
Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rube C, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004;104:634-41.
-
(2004)
Blood
, vol.104
, pp. 634-641
-
-
Pfreundschuh, M.1
Trumper, L.2
Kloess, M.3
Schmits, R.4
Feller, A.C.5
Rube, C.6
-
28
-
-
3042813710
-
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: Results of the NHL-B1 trial of the DSHNHL
-
Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rudolph C, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004;104:626-33.
-
(2004)
Blood
, vol.104
, pp. 626-633
-
-
Pfreundschuh, M.1
Trumper, L.2
Kloess, M.3
Schmits, R.4
Feller, A.C.5
Rudolph, C.6
-
29
-
-
33646004738
-
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group
-
Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-91.
-
(2006)
Lancet Oncol
, vol.7
, pp. 379-391
-
-
Pfreundschuh, M.1
Trumper, L.2
Osterborg, A.3
Pettengell, R.4
Trneny, M.5
Imrie, K.6
-
30
-
-
38549147027
-
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: A randomised controlled trial (RICOVER-60)
-
Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105-16.
-
(2008)
Lancet Oncol
, vol.9
, pp. 105-116
-
-
Pfreundschuh, M.1
Schubert, J.2
Ziepert, M.3
Schmits, R.4
Mohren, M.5
Lengfelder, E.6
-
31
-
-
0037165261
-
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
-
Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42.
-
(2002)
N Engl J Med
, vol.346
, pp. 235-242
-
-
Coiffier, B.1
Lepage, E.2
Briere, J.3
Herbrecht, R.4
Tilly, H.5
Bouabdallah, R.6
-
32
-
-
84878112490
-
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: A phase 3 comparison of dose intensification with 14-day versus 21-day cycles
-
Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 2013;381:1817-26.
-
(2013)
Lancet
, vol.381
, pp. 1817-1826
-
-
Cunningham, D.1
Hawkes, E.A.2
Jack, A.3
Qian, W.4
Smith, P.5
Mouncey, P.6
-
33
-
-
84876987456
-
Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): A randomised phase 3 trial
-
Delarue R, Tilly H, Mounier N, Petrella T, Salles G, Thieblemont C, et al. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol 2013;14:525-33.
-
(2013)
Lancet Oncol
, vol.14
, pp. 525-533
-
-
Delarue, R.1
Tilly, H.2
Mounier, N.3
Petrella, T.4
Salles, G.5
Thieblemont, C.6
-
34
-
-
82255186682
-
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): An open-label randomised phase 3 trial
-
Récher C, Coiffier B, Haioun C, Molina TJ, Fermé C, Casasnovas O, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet 2011;378:1858-67.
-
(2011)
Lancet
, vol.378
, pp. 1858-1867
-
-
Récher, C.1
Coiffier, B.2
Haioun, C.3
Molina, T.J.4
Fermé, C.5
Casasnovas, O.6
-
35
-
-
84877116726
-
Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: Results of a phase II Nordic Lymphoma Group study
-
Holte H, Leppa S, Bjorkholm M, Fluge O, Jyrkkio S, Delabie J, et al. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Ann Oncol 2013;24:1385-92.
-
(2013)
Ann Oncol
, vol.24
, pp. 1385-1392
-
-
Holte, H.1
Leppa, S.2
Bjorkholm, M.3
Fluge, O.4
Jyrkkio, S.5
Delabie, J.6
-
36
-
-
0037089314
-
Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: A pharmacodynamic approach with high efficacy
-
Wilson WH, Grossbard ML, Pittaluga S, Cole D, Pearson D, Drbohlav N, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood 2002;99:2685-93.
-
(2002)
Blood
, vol.99
, pp. 2685-2693
-
-
Wilson, W.H.1
Grossbard, M.L.2
Pittaluga, S.3
Cole, D.4
Pearson, D.5
Drbohlav, N.6
-
37
-
-
45749152667
-
Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers
-
Wilson WH, Dunleavy K, Pittaluga S, Hegde U, Grant N, Steinberg SM, et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol 2008;26:2717-24.
-
(2008)
J Clin Oncol
, vol.26
, pp. 2717-2724
-
-
Wilson, W.H.1
Dunleavy, K.2
Pittaluga, S.3
Hegde, U.4
Grant, N.5
Steinberg, S.M.6
-
38
-
-
33646539811
-
Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: A clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial
-
Oschlies I, Klapper W, Zimmermann M, Krams M, Wacker HH, Burkhardt B, et al. Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial. Blood 2006;107:4047-52.
-
(2006)
Blood
, vol.107
, pp. 4047-4052
-
-
Oschlies, I.1
Klapper, W.2
Zimmermann, M.3
Krams, M.4
Wacker, H.H.5
Burkhardt, B.6
-
39
-
-
84859715609
-
Roles of BCL6 in normal and transformed germinal center B cells
-
Basso K, Dalla-Favera R. Roles of BCL6 in normal and transformed germinal center B cells. Immunol Rev 2012;247:172-83.
-
(2012)
Immunol Rev
, vol.247
, pp. 172-183
-
-
Basso, K.1
Dalla-Favera, R.2
-
40
-
-
84894195316
-
Targeting BCL6 in diffuse large B-cell lymphoma: What does this mean for the future treatment?
-
Cerchietti L, Melnick A. Targeting BCL6 in diffuse large B-cell lymphoma: what does this mean for the future treatment? Expert Rev Hematol 2013;6:343-5.
-
(2013)
Expert Rev Hematol
, vol.6
, pp. 343-345
-
-
Cerchietti, L.1
Melnick, A.2
-
41
-
-
77950486830
-
A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo
-
Cerchietti LC, Ghetu AF, Zhu X, Da Silva GF, Zhong S, Matthews M, et al. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell 2010;17:400-11.
-
(2010)
Cancer Cell
, vol.17
, pp. 400-411
-
-
Cerchietti, L.C.1
Ghetu, A.F.2
Zhu, X.3
Da Silva, G.F.4
Zhong, S.5
Matthews, M.6
-
42
-
-
84899698307
-
Molecular dynamics analysis of the interaction between the human BCL6 BTB domain and its SMRT, NcoR and BCOR corepressors: The quest for a consensus dynamic pharmacophore
-
Granadino-Roldan JM, Obiol-Pardo C, Pinto M, Garzon A, Rubio-Martinez J. Molecular dynamics analysis of the interaction between the human BCL6 BTB domain and its SMRT, NcoR and BCOR corepressors: the quest for a consensus dynamic pharmacophore. J Mol Graph Model 2014;50:142-51.
-
(2014)
J Mol Graph Model
, vol.50
, pp. 142-151
-
-
Granadino-Roldan, J.M.1
Obiol-Pardo, C.2
Pinto, M.3
Garzon, A.4
Rubio-Martinez, J.5
-
43
-
-
79952430906
-
Inactivating mutations of acetyltransferase genes in B-cell lymphoma
-
Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011;471:189-95.
-
(2011)
Nature
, vol.471
, pp. 189-195
-
-
Pasqualucci, L.1
Dominguez-Sola, D.2
Chiarenza, A.3
Fabbri, G.4
Grunn, A.5
Trifonov, V.6
-
44
-
-
84887593197
-
Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma
-
Amengual JE, Clark-Garvey S, Kalac M, Scotto L, Marchi E, Neylon E, et al. Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma. Blood 2013;122:2104-13.
-
(2013)
Blood
, vol.122
, pp. 2104-2113
-
-
Amengual, J.E.1
Clark-Garvey, S.2
Kalac, M.3
Scotto, L.4
Marchi, E.5
Neylon, E.6
-
45
-
-
0043170892
-
BCL6 overexpression prevents increase in reactive oxygen species and inhibits apoptosis induced by chemotherapeutic reagents in B-cell lymphoma cells
-
Kurosu T, Fukuda T, Miki T, Miura O. BCL6 overexpression prevents increase in reactive oxygen species and inhibits apoptosis induced by chemotherapeutic reagents in B-cell lymphoma cells. Oncogene 2003;22:4459-68.
-
(2003)
Oncogene
, vol.22
, pp. 4459-4468
-
-
Kurosu, T.1
Fukuda, T.2
Miki, T.3
Miura, O.4
-
46
-
-
77951045229
-
The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma
-
Dunleavy K, Little RF, Pittaluga S, Grant N, Wayne AS, Carrasquillo JA, et al. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood 2010;115:3017-24.
-
(2010)
Blood
, vol.115
, pp. 3017-3024
-
-
Dunleavy, K.1
Little, R.F.2
Pittaluga, S.3
Grant, N.4
Wayne, A.S.5
Carrasquillo, J.A.6
-
47
-
-
84860573088
-
A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype
-
Wilson WH, Jung SH, Porcu P, Hurd D, Johnson J, Martin SE, et al. A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica 2012;97:758-65.
-
(2012)
Haematologica
, vol.97
, pp. 758-765
-
-
Wilson, W.H.1
Jung, S.H.2
Porcu, P.3
Hurd, D.4
Johnson, J.5
Martin, S.E.6
-
48
-
-
75749124332
-
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
-
Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010;42:181-5.
-
(2010)
Nat Genet
, vol.42
, pp. 181-185
-
-
Morin, R.D.1
Johnson, N.A.2
Severson, T.M.3
Mungall, A.J.4
An, J.5
Goya, R.6
-
49
-
-
84888303259
-
Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth
-
Garapaty-Rao S, Nasveschuk C, Gagnon A, Chan EY, Sandy P, Busby J, et al. Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth. Chem Biol 2013;20:1329-39.
-
(2013)
Chem Biol
, vol.20
, pp. 1329-1339
-
-
Garapaty-Rao, S.1
Nasveschuk, C.2
Gagnon, A.3
Chan, E.Y.4
Sandy, P.5
Busby, J.6
-
50
-
-
84890124372
-
Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma
-
Bohers E, Mareschal S, Bouzelfen A, Marchand V, Ruminy P, Maingonnat C, et al. Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma. Genes Chromosomes Cancer 2014;53:144-53.
-
(2014)
Genes Chromosomes Cancer
, vol.53
, pp. 144-153
-
-
Bohers, E.1
Mareschal, S.2
Bouzelfen, A.3
Marchand, V.4
Ruminy, P.5
Maingonnat, C.6
-
51
-
-
53749093794
-
Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma
-
Fu K, Weisenburger DD, Choi WW, Perry KD, Smith LM, Shi X, et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 2008;26:4587-94.
-
(2008)
J Clin Oncol
, vol.26
, pp. 4587-4594
-
-
Fu, K.1
Weisenburger, D.D.2
Choi, W.W.3
Perry, K.D.4
Smith, L.M.5
Shi, X.6
-
52
-
-
84909584269
-
Emerging role of infectious etiologies in the pathogenesis of marginal zone B-cell lymphomas
-
Zucca E, Bertoni F, Vannata B, Cavalli F. Emerging role of infectious etiologies in the pathogenesis of marginal zone B-cell lymphomas. Clin Cancer Res 2014;20:5207-16.
-
(2014)
Clin Cancer Res
, vol.20
, pp. 5207-5216
-
-
Zucca, E.1
Bertoni, F.2
Vannata, B.3
Cavalli, F.4
-
53
-
-
0035905313
-
Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells
-
Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001;194:1861-74.
-
(2001)
J Exp Med
, vol.194
, pp. 1861-1874
-
-
Davis, R.E.1
Brown, K.D.2
Siebenlist, U.3
Staudt, L.M.4
-
54
-
-
67650398258
-
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma
-
Dunleavy K, Pittaluga S, Czuczman MS, Dave SS, Wright G, Grant N, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 2009;113:6069-76.
-
(2009)
Blood
, vol.113
, pp. 6069-6076
-
-
Dunleavy, K.1
Pittaluga, S.2
Czuczman, M.S.3
Dave, S.S.4
Wright, G.5
Grant, N.6
-
55
-
-
79952154013
-
Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma
-
Ruan J, Martin P, Furman RR, Lee SM, Cheung K, Vose JM, et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 2011;29:690-7.
-
(2011)
J Clin Oncol
, vol.29
, pp. 690-697
-
-
Ruan, J.1
Martin, P.2
Furman, R.R.3
Lee, S.M.4
Cheung, K.5
Vose, J.M.6
-
56
-
-
73849145729
-
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
-
Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010;463:88-92.
-
(2010)
Nature
, vol.463
, pp. 88-92
-
-
Davis, R.E.1
Ngo, V.N.2
Lenz, G.3
Tolar, P.4
Young, R.M.5
Romesser, P.B.6
-
57
-
-
41149136296
-
Oncogenic CARD11 mutations in human diffuse large B cell lymphoma
-
Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008;319:1676-9.
-
(2008)
Science
, vol.319
, pp. 1676-1679
-
-
Lenz, G.1
Davis, R.E.2
Ngo, V.N.3
Lam, L.4
George, T.C.5
Wright, G.W.6
-
58
-
-
79551686422
-
Oncogenically active MYD88 mutations in human lymphoma
-
Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011;470:115-9.
-
(2011)
Nature
, vol.470
, pp. 115-119
-
-
Ngo, V.N.1
Young, R.M.2
Schmitz, R.3
Jhavar, S.4
Xiao, W.5
Lim, K.H.6
-
59
-
-
84905641032
-
Blockade of oncogenic IkappaB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors
-
Ceribelli M, Kelly PN, Shaffer AL, Wright GW, Xiao W, Yang Y, et al. Blockade of oncogenic IkappaB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. Proc Natl Acad Sci U S A 2014;111:11365-70.
-
(2014)
Proc Natl Acad Sci U S A
, vol.111
, pp. 11365-11370
-
-
Ceribelli, M.1
Kelly, P.N.2
Shaffer, A.L.3
Wright, G.W.4
Xiao, W.5
Yang, Y.6
-
60
-
-
84870856936
-
MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo
-
Fontan L, Yang C, Kabaleeswaran V, Volpon L, Osborne MJ, Beltran E, et al. MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. Cancer Cell 2012;22:812-24.
-
(2012)
Cancer Cell
, vol.22
, pp. 812-824
-
-
Fontan, L.1
Yang, C.2
Kabaleeswaran, V.3
Volpon, L.4
Osborne, M.J.5
Beltran, E.6
-
61
-
-
84874585216
-
The Bruton's Tyrosine Kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): Interim results of a multicenter, open-label, phase 2 study
-
[abstract]
-
Wilson W, Gerecitano J, Goy A, Vos Sd, Kenkre V, Barr P, et al. The Bruton's Tyrosine Kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study [abstract]. Blood (ASH Annual Meeting Abstracts) 2012;120:686.
-
(2012)
Blood (ASH Annual Meeting Abstracts)
, vol.120
, pp. 686
-
-
Wilson, W.1
Gerecitano, J.2
Goy, A.3
Vos, S.4
Kenkre, V.5
Barr, P.6
-
62
-
-
84897055483
-
Targeting Bruton's tyrosine kinase in B cell malignancies
-
Hendriks RW, Yuvaraj S, Kil LP. Targeting Bruton's tyrosine kinase in B cell malignancies. Nat Rev Cancer 2014;14:219-32.
-
(2014)
Nat Rev Cancer
, vol.14
, pp. 219-232
-
-
Hendriks, R.W.1
Yuvaraj, S.2
Kil, L.P.3
-
63
-
-
77951002653
-
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
-
Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010;115:2578-85.
-
(2010)
Blood
, vol.115
, pp. 2578-2585
-
-
Friedberg, J.W.1
Sharman, J.2
Sweetenham, J.3
Johnston, P.B.4
Vose, J.M.5
Lacasce, A.6
-
64
-
-
78149239933
-
Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium
-
Smith SM, van Besien K, Karrison T, Dancey J, McLaughlin P, Younes A, et al. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol 2010;28:4740-6.
-
(2010)
J Clin Oncol
, vol.28
, pp. 4740-4746
-
-
Smith, S.M.1
Van Besien, K.2
Karrison, T.3
Dancey, J.4
McLaughlin, P.5
Younes, A.6
-
65
-
-
23944481410
-
Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
-
Witzig TE, Geyer SM, Ghobrial I, Inwards DJ, Fonseca R, Kurtin P, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005;23:5347-56.
-
(2005)
J Clin Oncol
, vol.23
, pp. 5347-5356
-
-
Witzig, T.E.1
Geyer, S.M.2
Ghobrial, I.3
Inwards, D.J.4
Fonseca, R.5
Kurtin, P.6
-
66
-
-
84875651324
-
Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma
-
Barnes JA, Jacobsen E, Feng Y, Freedman A, Hochberg EP, LaCasce AS, et al. Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma. Haematologica 2013;98:615-9.
-
(2013)
Haematologica
, vol.98
, pp. 615-619
-
-
Barnes, J.A.1
Jacobsen, E.2
Feng, Y.3
Freedman, A.4
Hochberg, E.P.5
LaCasce, A.S.6
-
67
-
-
84896693794
-
PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma
-
Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014;370:1008-18.
-
(2014)
N Engl J Med
, vol.370
, pp. 1008-1018
-
-
Gopal, A.K.1
Kahl, B.S.2
De Vos, S.3
Wagner-Johnston, N.D.4
Schuster, S.J.5
Jurczak, W.J.6
-
68
-
-
78751553221
-
CAL-101, a p110 selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
-
Lannutti BJ, Meadows SA, Herman SEM, Kashishian A, Steiner B, Johnson AJ, et al. CAL-101, a p110 selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2010;117:591-4.
-
(2010)
Blood
, vol.117
, pp. 591-594
-
-
Lannutti, B.J.1
Meadows, S.A.2
Herman, S.E.M.3
Kashishian, A.4
Steiner, B.5
Johnson, A.J.6
-
69
-
-
84862152044
-
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma
-
Yang Y, Shaffer AL 3rd, Emre NC, Ceribelli M, Zhang M, Wright G, et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 2012;21:723-37.
-
(2012)
Cancer Cell
, vol.21
, pp. 723-737
-
-
Yang, Y.1
Shaffer 3rd, A.L.2
Emre, N.C.3
Ceribelli, M.4
Zhang, M.5
Wright, G.6
-
70
-
-
80053502780
-
Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype
-
Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, Pileri SA, Malik F, Macon WR, et al. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer 2011;117:5058-66.
-
(2011)
Cancer
, vol.117
, pp. 5058-5066
-
-
Hernandez-Ilizaliturri, F.J.1
Deeb, G.2
Zinzani, P.L.3
Pileri, S.A.4
Malik, F.5
Macon, W.R.6
-
71
-
-
83555173455
-
Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: Phase I study
-
Nowakowski GS, LaPlant B, Habermann TM, Rivera CE, Macon WR, Inwards DJ, et al. Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Leukemia 2011;25:1877-81.
-
(2011)
Leukemia
, vol.25
, pp. 1877-1881
-
-
Nowakowski, G.S.1
LaPlant, B.2
Habermann, T.M.3
Rivera, C.E.4
Macon, W.R.5
Inwards, D.J.6
-
72
-
-
84901391325
-
Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: Results of the REAL07 open-label, multicentre, phase 2 trial
-
Vitolo U, Chiappella A, Franceschetti S, Carella AM, Baldi I, Inghirami G, et al. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. Lancet Oncol 2014;15:730-7.
-
(2014)
Lancet Oncol
, vol.15
, pp. 730-737
-
-
Vitolo, U.1
Chiappella, A.2
Franceschetti, S.3
Carella, A.M.4
Baldi, I.5
Inghirami, G.6
-
73
-
-
84923922267
-
Effect of lenalidomide combined with R-CHOP (R2CHOP) on negative prognostic impact of non-germinal venter (non-GCB) phenotype in newly diagnosed diffuse large B-cell lymphoma: A phase 2 study
-
Nowakowski GS, LaPlant B, Macon WR, Reeder CB, Foran JM, Nelson GD, et al. Effect of lenalidomide combined with R-CHOP (R2CHOP) on negative prognostic impact of non-germinal venter (non-GCB) phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase 2 study. J Clin Oncol 32:5s, 2014 (suppl; abstr 8520).
-
(2014)
J Clin Oncol
, vol.32
, pp. 5s
-
-
Nowakowski, G.S.1
LaPlant, B.2
Macon, W.R.3
Reeder, C.B.4
Foran, J.M.5
Nelson, G.D.6
-
74
-
-
57849149430
-
Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
-
Klapper W, Stoecklein H, Zeynalova S, Ott G, Kosari F, Rosenwald A, et al. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Leukemia 2008;22:2226-9.
-
(2008)
Leukemia
, vol.22
, pp. 2226-2229
-
-
Klapper, W.1
Stoecklein, H.2
Zeynalova, S.3
Ott, G.4
Kosari, F.5
Rosenwald, A.6
-
75
-
-
70449589073
-
MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy
-
Savage KJ, Johnson NA, Ben-Neriah S, Connors JM, Sehn LH, Farinha P, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009;114:3533-7.
-
(2009)
Blood
, vol.114
, pp. 3533-3537
-
-
Savage, K.J.1
Johnson, N.A.2
Ben-Neriah, S.3
Connors, J.M.4
Sehn, L.H.5
Farinha, P.6
-
76
-
-
84884491827
-
Interpreting MYC and BCL2 in diffuse large B-cell lymphoma
-
Lai C, Grant C, Dunleavy K. Interpreting MYC and BCL2 in diffuse large B-cell lymphoma. Leuk Lymphoma 2013;54:2091-2.
-
(2013)
Leuk Lymphoma
, vol.54
, pp. 2091-2092
-
-
Lai, C.1
Grant, C.2
Dunleavy, K.3
-
77
-
-
77954752069
-
Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab
-
Barrans S, Crouch S, Smith A, Turner K, Owen R, Patmore R, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 2010;28:3360-5.
-
(2010)
J Clin Oncol
, vol.28
, pp. 3360-3365
-
-
Barrans, S.1
Crouch, S.2
Smith, A.3
Turner, K.4
Owen, R.5
Patmore, R.6
-
78
-
-
84907599085
-
Double hit lymphoma: The MD Anderson Cancer Center clinical experience
-
Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, et al. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol 2014;166:891-901.
-
(2014)
Br J Haematol
, vol.166
, pp. 891-901
-
-
Oki, Y.1
Noorani, M.2
Lin, P.3
Davis, R.E.4
Neelapu, S.S.5
Ma, L.6
-
79
-
-
84867088456
-
Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
-
Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012;30:3452-9.
-
(2012)
J Clin Oncol
, vol.30
, pp. 3452-3459
-
-
Johnson, N.A.1
Slack, G.W.2
Savage, K.J.3
Connors, J.M.4
Ben-Neriah, S.5
Rogic, S.6
-
80
-
-
84867060272
-
Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
-
Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012;30:3460-7.
-
(2012)
J Clin Oncol
, vol.30
, pp. 3460-3467
-
-
Green, T.M.1
Young, K.H.2
Visco, C.3
Xu-Monette, Z.Y.4
Orazi, A.5
Go, R.S.6
-
81
-
-
84887482359
-
Low-intensity therapy in adults with Burkitt's lymphoma
-
Dunleavy K, Pittaluga S, Shovlin M, Steinberg SM, Cole D, Grant C, et al. Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med 2013;369:1915-25.
-
(1915)
N Engl J Med
, vol.2013
, pp. 369
-
-
Dunleavy, K.1
Pittaluga, S.2
Shovlin, M.3
Steinberg, S.M.4
Cole, D.5
Grant, C.6
-
82
-
-
84855281681
-
MYC +aggressive B-cell lymphomas: Novel therapy of untreated Burkitt lymphoma (BL) and MYC + diffuse large B-cell lymphoma (DLBCL) with DA-EPOCH-R
-
[abstract]
-
Dunleavy K, Pittaluga S, Wayne A, Shovlin M, Johnson J, Little R, et al. MYC +aggressive B-cell lymphomas: novel therapy of untreated Burkitt lymphoma (BL) and MYC + diffuse large B-cell lymphoma (DLBCL) with DA-EPOCH-R [abstract]. Ann Oncol 2011;22 Suppl 4:iv6. Abstract nr 71.
-
(2011)
Ann Oncol
, vol.22
, pp. iv6
-
-
Dunleavy, K.1
Pittaluga, S.2
Wayne, A.3
Shovlin, M.4
Johnson, J.5
Little, R.6
-
83
-
-
84879385620
-
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: A report from The International DLBCL Rituximab-CHOP Consortium Program
-
Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 2013;121:4021-31.
-
(2013)
Blood
, vol.121
, pp. 4021-4031
-
-
Hu, S.1
Xu-Monette, Z.Y.2
Tzankov, A.3
Green, T.4
Wu, L.5
Balasubramanyam, A.6
-
84
-
-
84901842119
-
Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors
-
Tolani B, Gopalakrishnan R, Punj V, Matta H, Chaudhary PM. Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors. Oncogene 2014;29:2928-37.
-
(2014)
Oncogene
, vol.29
, pp. 2928-2937
-
-
Tolani, B.1
Gopalakrishnan, R.2
Punj, V.3
Matta, H.4
Chaudhary, P.M.5
-
85
-
-
84892916318
-
Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas
-
Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, et al. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol 2014;32:44-50.
-
(2014)
J Clin Oncol
, vol.32
, pp. 44-50
-
-
Friedberg, J.W.1
Mahadevan, D.2
Cebula, E.3
Persky, D.4
Lossos, I.5
Agarwal, A.B.6
-
86
-
-
78649630259
-
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: A phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
-
Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010;11:1149-59.
-
(2010)
Lancet Oncol
, vol.11
, pp. 1149-1159
-
-
Wilson, W.H.1
O'Connor, O.A.2
Czuczman, M.S.3
LaCasce, A.S.4
Gerecitano, J.F.5
Leonard, J.P.6
-
87
-
-
0033571348
-
Treatment and clinical management of primary mediastinal large B-cell lymphomawith sclerosis: MACOP-Bregimen and mediastinal radiotherapy monitored by (67)Gallium scan in 50 patients
-
Zinzani PL, Martelli M, Magagnoli M, Pescarmona E, Scaramucci L, Palombi F, et al. Treatment and clinical management of primary mediastinal large B-cell lymphomawith sclerosis: MACOP-Bregimen and mediastinal radiotherapy monitored by (67)Gallium scan in 50 patients. Blood 1999;94:3289-93.
-
(1999)
Blood
, vol.94
, pp. 3289-3293
-
-
Zinzani, P.L.1
Martelli, M.2
Magagnoli, M.3
Pescarmona, E.4
Scaramucci, L.5
Palombi, F.6
-
88
-
-
0037567428
-
Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease
-
Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003;348:2386-95.
-
(2003)
N Engl J Med
, vol.348
, pp. 2386-2395
-
-
Diehl, V.1
Franklin, J.2
Pfreundschuh, M.3
Lathan, B.4
Paulus, U.5
Hasenclever, D.6
-
89
-
-
10744224539
-
Primary mediastinal large B-cell lymphoma (PMLBCL): Long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B
-
Todeschini G, Secchi S, Morra E, Vitolo U, Orlandi E, Pasini F, et al. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer 2004;90:372-6.
-
(2004)
Br J Cancer
, vol.90
, pp. 372-376
-
-
Todeschini, G.1
Secchi, S.2
Morra, E.3
Vitolo, U.4
Orlandi, E.5
Pasini, F.6
-
90
-
-
0036906427
-
Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: A retrospective multinational study on 426 previously untreated patients
-
Zinzani PL, Martelli M, Bertini M, Gianni AM, Devizzi L, Federico M, et al. Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica 2002;87:1258-64.
-
(2002)
Haematologica
, vol.87
, pp. 1258-1264
-
-
Zinzani, P.L.1
Martelli, M.2
Bertini, M.3
Gianni, A.M.4
Devizzi, L.5
Federico, M.6
-
91
-
-
27244432753
-
Primary mediastinal large B-cell lymphoma: Optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999
-
Hamlin PA, Portlock CS, Straus DJ, Noy A, Singer A, Horwitz SM, et al. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999. Br J Haematol 2005;130:691-9.
-
(2005)
Br J Haematol
, vol.130
, pp. 691-699
-
-
Hamlin, P.A.1
Portlock, C.S.2
Straus, D.J.3
Noy, A.4
Singer, A.5
Horwitz, S.M.6
-
92
-
-
79952029773
-
Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: Results of the Mabthera International Trial Group study
-
Rieger M, Osterborg A, Pettengell R, White D, Gill D, Walewski J, et al. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann Oncol 2011;22:664-70.
-
(2011)
Ann Oncol
, vol.22
, pp. 664-670
-
-
Rieger, M.1
Osterborg, A.2
Pettengell, R.3
White, D.4
Gill, D.5
Walewski, J.6
-
93
-
-
84857386754
-
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: The emerging standard of care
-
Vassilakopoulos TP, Pangalis GA, Katsigiannis A, Papageorgiou SG, Constantinou N, Terpos E, et al. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care. Oncologist 2012;17:239-49.
-
(2012)
Oncologist
, vol.17
, pp. 239-249
-
-
Vassilakopoulos, T.P.1
Pangalis, G.A.2
Katsigiannis, A.3
Papageorgiou, S.G.4
Constantinou, N.5
Terpos, E.6
-
94
-
-
84894480056
-
Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease
-
Soumerai JD, Hellmann MD, Feng Y, Sohani AR, Toomey CE, Barnes JA, et al. Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease. Leuk Lymphoma 2014;55:538-43.
-
(2014)
Leuk Lymphoma
, vol.55
, pp. 538-543
-
-
Soumerai, J.D.1
Hellmann, M.D.2
Feng, Y.3
Sohani, A.R.4
Toomey, C.E.5
Barnes, J.A.6
-
95
-
-
78951483097
-
Sequential dose-dende R-CHOP followed by ICE consolidation (MSKCC Protocol 01-142) without radiotherapy for patients with primary mediastinal large B-cell lymphoma
-
[abstract]
-
Moskowitz C, Hamlin PA, Maraguilia J, Meikle J, Zelenetz AD. Sequential dose-dende R-CHOP followed by ICE consolidation (MSKCC Protocol 01-142) without radiotherapy for patients with primary mediastinal large B-cell lymphoma [abstract]. Blood (ASH Annual Meeting Abstracts) 2010;116:420.
-
(2010)
Blood (ASH Annual Meeting Abstracts)
, vol.116
, pp. 420
-
-
Moskowitz, C.1
Hamlin, P.A.2
Maraguilia, J.3
Meikle, J.4
Zelenetz, A.D.5
-
96
-
-
84905842871
-
[18F] fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: Results of the International Extranodal Lymphoma Study Group IELSG-26 Study
-
Martelli M, Ceriani L, Zucca E, Zinzani PL, Ferreri AJ, Vitolo U, et al. [18F] fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. J Clin Oncol 2014;32:1769-75.
-
(2014)
J Clin Oncol
, vol.32
, pp. 1769-1775
-
-
Martelli, M.1
Ceriani, L.2
Zucca, E.3
Zinzani, P.L.4
Ferreri, A.J.5
Vitolo, U.6
-
97
-
-
79951492419
-
Morbidity and mortality in long-term survivors of Hodgkin lymphoma: A report from the Childhood Cancer Survivor Study
-
Castellino SM, Geiger AM, Mertens AC, Leisenring WM, Tooze JA, Goodman P, et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood 2011;117:1806-16.
-
(2011)
Blood
, vol.117
, pp. 1806-1816
-
-
Castellino, S.M.1
Geiger, A.M.2
Mertens, A.C.3
Leisenring, W.M.4
Tooze, J.A.5
Goodman, P.6
-
98
-
-
77949887677
-
Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy
-
O'Brien MM, Donaldson SS, Balise RR, Whittemore AS, Link MP. Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy. J Clin Oncol 2010;28:1232-9.
-
(2010)
J Clin Oncol
, vol.28
, pp. 1232-1239
-
-
O'Brien, M.M.1
Donaldson, S.S.2
Balise, R.R.3
Whittemore, A.S.4
Link, M.P.5
-
99
-
-
84875962936
-
Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma
-
Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 2013;368:1408-16.
-
(2013)
N Engl J Med
, vol.368
, pp. 1408-1416
-
-
Dunleavy, K.1
Pittaluga, S.2
Maeda, L.S.3
Advani, R.4
Chen, C.C.5
Hessler, J.6
-
101
-
-
84884260608
-
STAT6-mediated BCL6 repression in primary mediastinal B-cell lymphoma (PMBL)
-
Ritz O, Rommel K, Dorsch K, Kelsch E, Melzner J, Buck M, et al. STAT6-mediated BCL6 repression in primary mediastinal B-cell lymphoma (PMBL). Oncotarget 2013;4:1093-102.
-
(2013)
Oncotarget
, vol.4
, pp. 1093-1102
-
-
Ritz, O.1
Rommel, K.2
Dorsch, K.3
Kelsch, E.4
Melzner, J.5
Buck, M.6
-
102
-
-
77951010885
-
Aggressive lymphomas
-
Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med 2010;362:1417-29.
-
(2010)
N Engl J Med
, vol.362
, pp. 1417-1429
-
-
Lenz, G.1
Staudt, L.M.2
|